Bryce, A. H., Alumkal, J. J., Armstrong, A., Higano, C. S., Iversen, P., Sternberg, C. N., … Beer, T. M. (2016). A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study. In Annals of Oncology (Vol. 27, p. vi258). https://doi.org/10.1093/annonc/mdw372.44

Bryce, A. H., J. J. Alumkal, A. Armstrong, C. S. Higano, P. Iversen, C. N. Sternberg, D. E. Rathkopf, et al. “A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study.” In Annals of Oncology, 27:vi258, 2016. https://doi.org/10.1093/annonc/mdw372.44.

Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study. In: Annals of Oncology. 2016. p. vi258.

Bryce, A. H., et al. “A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study.” Annals of Oncology, vol. 27, 2016, p. vi258. Scopus, doi:10.1093/annonc/mdw372.44.

Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf DE, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study. Annals of Oncology. 2016. p. vi258.